Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) robust pipeline and attractive valuation has prompted an analyst at HC Wainwright to join the bullish camp.